Subscribe Us

header ads

Recents

header ads

Cell and Gene Therapy Market Size At Around US$ 93.78 Bn In 2030

The cell and gene therapy market would grow at a CAGR of 22.41% over the predicted time frame. The market is expected to increase in value from US$ 18.61 Bn in 2022 to US$ 93.78 Bn in 2030.

Cell And Gene Therapy Market Size 2022 to 2030

 

The on cell and gene therapy Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/2445

A recent report provides crucial insights along with application based and forecast information in the Global Cell and gene therapy Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Cell and gene therapy market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Cell and gene therapy market are included as given below:

Cell and gene therapy Market Key Players

  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Biogen Inc.
  • CORESTEM Inc.
  • Dendreon Pharmaceuticals LLC.
  • Helixmith Co. Ltd.
  • JCR Pharmaceuticals Co. Ltd.
  • Kolon TissueGene Inc.
  • Novartis AG
  • Pfizer Inc.

Market Segments

By Therapy Type

  • Cell Therapy
    • Stem Cells
    • T Cells
    • Dendritic Cells
    • NK Cells
    • Tumor Cells
  • Gene Therapy

By Therapeutic class

  • Cardiovascular Disease
  • Cancer
  • Genetic Disorder
  • Rare Diseases
  • Oncology
  • Hematology
  • Ophthalmology
  • Infectious Disease
  • Neurological Disorders

By Delivery Method

  • In Vivo
  • Ex vivo

By End-Users

  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • Others

By Region 

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Report Objectives

  • To define, describe, and forecast the global cell and gene therapy market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the cell and gene therapy market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell and Gene Therapy Market 

5.1. COVID-19 Landscape: Cell and Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cell and Gene Therapy Market, By Therapy Type

8.1. Cell and Gene Therapy Market, by Therapy Type, 2022-2030

8.1.1. Cell Therapy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Gene Therapy

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Cell and Gene Therapy Market, By Therapeutic class

9.1. Cell and Gene Therapy Market, by Therapeutic class, 2022-2030

9.1.1. Cardiovascular Disease

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Cancer

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Genetic Disorder

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Rare Diseases

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Oncology

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Oncology

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Ophthalmology

9.1.7.1. Market Revenue and Forecast (2017-2030)

9.1.8. Infectious Disease

9.1.8.1. Market Revenue and Forecast (2017-2030)

9.1.9. Neurological Disorders

9.1.9.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Cell and Gene Therapy Market, By Delivery Method 

10.1. Cell and Gene Therapy Market, by Delivery Method, 2022-2030

10.1.1. In Vivo

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Ex vivo

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Cell and Gene Therapy Market, By End-Users 

11.1. Cell and Gene Therapy Market, by End-Users, 2022-2030

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Cancer Care Centers

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Wound Care Centers

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Cell and Gene Therapy Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.1.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.1.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.1.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.1.6.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.2.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.2.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.2.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.2.6.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.2.7.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.2.8.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.3.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.3.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.3.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.3.6.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.3.7.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.3.8.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.4.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.4.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.4.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.4.6.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.4.7.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.4.8.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.5.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.5.6.4. Market Revenue and Forecast, by End-Users (2017-2030)

Chapter 13. Company Profiles

13.1. Alnylam Pharmaceuticals Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Amgen Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Biogen Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. CORESTEM Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Dendreon Pharmaceuticals LLC.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Helixmith Co. Ltd.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. JCR Pharmaceuticals Co. Ltd.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Kolon TissueGene Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Novartis AG

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Pfizer Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

Post a Comment

0 Comments